IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
Eli Lilly surges on Retatrutide data, showing surgery-like weight loss
Eli Lilly and Company shares surged on May 30, 2026. The company released breakthrough clinical trial data for its next-generation obesity drug,...
Pfizer strikes $10 billion Innovent deal, securing 12 Chinese cancer treatments
Pfizer partnered with Chinese drugmaker Innovent Biologics on a strategic alliance worth over $10 billion. The collaboration aims to develop up to 12...
Bristol Myers Squibb Cuts Multiple Myeloma Risk 52%, Validating New Drug Class
Bristol Myers Squibb announced positive results from the Phase 3 SUCCESSOR-2 trial for mezigdomide. The study evaluated the treatment for patients with...
Johnson & Johnson Wins FDA Approval for TREMFYA to Prevent Joint Damage
Johnson & Johnson received FDA approval for a supplemental Biologics License Application for its drug TREMFYA (guselkumab). The expanded label includes...
Eli Lilly Hits Record High, Securing Key CVS Obesity Drug Coverage
CVS Caremark will add Eli Lilly’s new oral obesity pill, Foundayo, to its formulary. The pharmacy benefit manager (PBM) also restored coverage for the...
Eli Lilly bets $3.8 billion on vaccines, using obesity drug cash
Eli Lilly agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company for a potential $3.83 billion. The company is using significant cash flow from its...
Eli Lilly buys three vaccine firms for $4B, diversifying beyond Mounjaro success
Eli Lilly signed agreements to acquire three private vaccine companies for nearly $4 billion. The deal includes the acquisition of Curevo, LimmaTech...